Search

C25H30O6, orthorhombic, Pna21 (no. 33), a = 7.556(2) Å, b = 37.198(12) Å, c = 8.113(2) Å, V = 2280.2(11) Å3, Z = 4, Rgt(F) = 0.0610, wRref(F2) = 0.1634, T = 170 K.

The ability of soil moisture (SM) to affect precipitation (P) is a vital part of the water-energy cycles. Accurately quantifying this coupling enhances the ability to predict hydroclimatic extremes like floods and droughts. In this study, the ability of soil moisture to affect precipitation (SM-P) is characterized by two parts: the influence of soil moisture on evapotranspiration (SM-ET), and the influence of evapotranspiration on precipitation (ET-P). We determined localized ET-P by incorporating the coupling between latent heat flux (LH) and LCL height, to optimize the estimation of the SM-P. This approach links SM more closely to P by considering the influence of surface fluxes. The results indicate that CMIP6 models exhibited the anticipated hotspot patterns for the three coupling metrics in transition regions. However, we observed that climate models generally exhibit weaker SM-P coupling compared to reanalysis models. Both SM-ET and SM-P showcase higher values wherein wet climate regions during dry years, and the converse occurs in dry regions. Due to sensitivity to climate change, the ET-P exhibits a more pronounced upward trend in the future. This study helps understand P's response to SM shifts in climate models, crucial for predicting hydrological extremes and coupled global warming impact. [ABSTRACT FROM AUTHOR]

C25H30O6, orthorhombic, Pna21 (no. 33), a = 7.556(2) Å, b = 37.198(12) Å, c = 8.113(2) Å, V = 2280.2(11) Å3, Z = 4, Rgt(F) = 0.0610, wRref(F2) = 0.1634, T = 170 K. [ABSTRACT FROM AUTHOR]

C25H30O6, orthorhombic, Pna21 (no. 33), a = 7.556(2) Å, b = 37.198(12) Å, c = 8.113(2) Å, V = 2280.2(11) Å3, Z = 4, Rgt(F) = 0.0610, wRref(F2) = 0.1634, T = 170 K. [ABSTRACT FROM AUTHOR]

C25H30O6, orthorhombic, Pna21 (no. 33), a = 7.556(2) Å, b = 37.198(12) Å, c = 8.113(2) Å, V = 2280.2(11) Å3, Z = 4, Rgt(F) = 0.0610, wRref(F2) = 0.1634, T = 170 K. [ABSTRACT FROM AUTHOR]

C25H30O6, orthorhombic, Pna21 (no. 33), a = 7.556(2) Å, b = 37.198(12) Å, c = 8.113(2) Å, V = 2280.2(11) Å3, Z = 4, Rgt(F) = 0.0610, wRref(F2) = 0.1634, T = 170 K. [ABSTRACT FROM AUTHOR]

Rationale: TAFRO syndrome is a systemic inflammatory disorder, manifesting as thrombocytopenia (t), anasarca (a), fever (f), reticulin myelofibrosis/renal insufficiency (r), and organomegaly (o), and considered as a unique clinical subtype of idiopathic multicentric Castleman disease (iMCD). Such syndrome gave rise to a clinical picture similar to that of either a connective tissue disease or an autoimmune disease., Patient Concerns: A Chinese young female initially presenting with arthralgia, Raynaud phenomenon, generalized edema, and a positive anti-small nuclear ribonucleoprotein particle antibody was diagnosed as mixed connective tissue disease. The kidney biopsy showed thrombotic microangiopathy. Bone marrow smear showed bone marrow hyperplasia and biopsy revealed suspected light chain restricted expression, megakaryocyte proliferation, and moderate to severe bone marrow fibrosis. A lymph node biopsy was conducted and the histopathological findings were consistent with the subtype of mixed Castleman disease. The clinical symptoms were relieved after regular chemotherapy., Diagnoses: After above examination results and clinical manifestations, the final diagnoses was TAFRO syndrome., Intervention: The she was started on chemotherapy with bortezomib, cyclophosphamide, and dexamethasone., Outcome: After chemotherapy, symptoms such as thrombocytopenia, hematuria and proteinuria disappeared, lymphadenopathy and VEGF level decreased, and bone marrow fibrosis relieved., Lessons: Our case illustrated the first cases of shared characteristics of mixed connective tissue disease and iMCD-TAFRO syndrome. Cytokines may play a role in the shared pathogenicity of the iMCD-TAFRO syndrome and systemic autoimmune diseases. Therapy directly against inflammatory factors such as corticosteroids or chemotherapy have an important therapeutic implication., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)